PYC.LSE · Physiomics Plc

-

Please sign in to comment on PYC.LSE

1 Comment

Admin

4 years, 1 month ago

Physiomics Plc is currently in a long term downtrend where the price is trading 8.4% below its 200 day moving average.

From a valuation standpoint, the stock is 98.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 7.1.

Physiomics Plc's total revenue sank by 0.0% to $172K since the same quarter in the previous year.

Its net income has dropped by 0.0% to $-41K since the same quarter in the previous year.

Finally, its free cash flow grew by 96.6% to $28K since the same quarter in the previous year.

Based on the above factors, Physiomics Plc gets an overall score of 2/5.

Sector	Healthcare
Industry	Biotechnology
ISIN	GB00BDR6W943
Exchange	LSE
CurrencyCode	GBP

Market Cap	1M
PE Ratio	None
Beta	0.67
Target Price	0.2
Dividend Yield	None

ABOUT

Physiomics Plc

Physiomics Plc provides consulting services to pharmaceutical companies in the areas of outsourced quantitative pharmacology and computational biology in the United Kingdom, the United States, and the European Union Switzerland. The company offers modeling, simulation, and data analysis services covering various ranges of oncology research and development using its proprietary Virtual Tumour predictive software. It also develops technology for use in the field of personalized medicine. The company was incorporated in 2001 and is based in Oxford, the United Kingdom.

PYC.LSE · Physiomics Plc

-

Physiomics Plc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Physiomics Plc using a moving average strategy